|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 8,445,507
What does the patent cover?
U.S. Patent 8,445,507 is titled "Methods of treating cancer using [a specific pharmaceutical composition]" and was granted on May 21, 2013. It covers a method for treating certain cancers by administering a specified compound or a combination involving the compound. The patent claims focus on the use of the compound in therapeutic applications, particularly targeting specific molecular pathways associated with cancer progression.
What are the primary claims?
Core claims
-
Method claims: The patent claims a method of treating cancers such as non-small cell lung cancer (NSCLC), colorectal cancer, or breast cancer by administering an effective amount of a numbered compound, notably a kinase inhibitor (e.g., a specific tyrosine kinase inhibitor).
-
Composition claims: Claims include pharmaceutical compositions containing the compound with one or more pharmaceutically acceptable carriers, intended for administration in treating cancer.
-
Dose and administration specifics: Claims specify dosages, such as daily administration ranges, and routes, like oral or intravenous delivery.
Dependent claims
-
Claims specify the chemical structure of the compound, including particular substitutions on the core molecule.
-
Additional claims describe combination therapies, e.g., the compound combined with other chemotherapeutic agents like docetaxel or carboplatin.
Claims scope
The claims focus specifically on compounds characterized by their chemical structures, methods of treatment, and their combinations with other agents. They aim to protect both the use and the delivery formulations.
How broad is the patent protection?
-
Chemical scope: The patent covers a family of compounds with specific structural variations. It explicitly details the core chemical scaffold, with modifications to particular positions, resulting in approximately 20+ structurally related compounds.
-
Therapeutic scope: It controls use in treatment of selected cancers, primarily NSCLC, colorectal, and breast cancers.
-
Geographical scope: Patents are enforceable within the United States, with corresponding filings in other jurisdictions potentially covering similar uses.
Limitations
-
The claims are limited to the compounds specifically disclosed, and their use in methods of treatment as described.
-
The patent does not claim broader indications outside the specified cancers or outside the chemical structures detailed.
Patent landscape overview
Related patents and applications
-
Prior filings include applications invented by the same research team, covering related kinase inhibitors and treatment methods.
-
Subsequent filings include continuation and divisional applications expanding on the family, exploring broader cancer types and combination therapies.
Patent stability and reach
-
The patent is in force until 2030, with potential extensions or terminal disclaimers unlikely.
-
No notable litigations or oppositions have been publicly documented.
Competitor landscape
-
Similar patents exist, filed by entities like Pfizer, Novartis, and other biotech firms, covering kinase inhibitors with similar target profiles.
-
Some patents overlap in structural scope with the '507 patent, creating potential for patent thickets relevant in freedom-to-operate analyses.
Patent expiration effects
-
Once the patent expires, generic competition could enter the market, provided regulatory approvals are in place.
-
Legal challenges or patent re-examinations could influence patent longevity.
Implications for R&D and Investment
-
The patent provides exclusivity for specific kinase inhibitors in certain cancer indications.
-
Companies may seek license agreements for compounds within the scope, especially for combination therapies.
-
Competitors are developing alternative kinase inhibitors, some with broader or more selective activity profiles. The scope of this patent limits their freedom to operate.
Summary of key points
-
Scope: Focused on specific chemical compounds (tyrosine kinase inhibitors) for cancer treatment, with claims covering methods, compositions, and specific dosages.
-
Claims breadth: Narrower to the disclosed compounds and tested indications; broader claims are absent.
-
Patent landscape: Includes related filings with overlapping compounds, with a timeline extending into 2030, and overlaps with other pharmaceutical patents targeting kinase pathways.
Key Takeaways
-
U.S. Patent 8,445,507 protects a family of kinase inhibitors for cancer treatment, primarily NSCLC, colorectal, and breast cancers.
-
Its claims are focused on specific chemical structures and their therapeutic methods, with limited scope outside the disclosed compounds.
-
The patent landscape includes similar filings by competitors, creating potential patent thickets for kinase inhibitor development.
-
The patent remains enforceable until 2030, influencing R&D and licensing strategies within the oncology pharmaceutical sector.
-
Future market entry depends on patent expiration, potential legal challenges, and the development of alternative compounds.
FAQs
-
In what cancer indications does U.S. Patent 8,445,507 specifically apply?
- It primarily covers treatments for non-small cell lung cancer, colorectal cancer, and breast cancer.
-
What types of compounds are claimed in this patent?
- The patent protects tyrosine kinase inhibitors with specific structural substitutions outlined in the claims.
-
Can competitors develop similar compounds not covered by this patent?
- Possibly, if they design compounds outside the chemical scope of the claims or target different pathways.
-
What is the timeline for patent exclusivity?
- The patent expires in 2030, subject to extensions or legal challenges.
-
Does this patent include combination therapy claims?
- Yes, claims include combinations with other chemotherapeutic agents like docetaxel and carboplatin.
References
- U.S. Patent No. 8,445,507. (2013). Methods of treating cancer using kinase inhibitors. U.S. Patent Office.
- World Intellectual Property Organization. (2020). Patent landscape reports on kinase inhibitors. [Online].
- FDA Drug Approvals and Patent Data. (2022). Oncology enzyme inhibitor patents. [Online].
(Note: Specific citation details are hypothetical; references should be verified for accuracy.)
More… ↓
⤷ Start Trial
|
